Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00340613 · ClinicalTrials.gov registry record · Phase 4

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

A Phase 4 study of Type 1 Diabetes, sponsored by Baylor College of Medicine.

Completed
Registry status
Phase 4
Development phase
36
Enrollment target
1
Study location

NCT00340613 is a Phase 4 study of Type 1 Diabetes that has completed, run by Baylor College of Medicine. The registered enrollment target is 36 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00340613, a Phase 4 study of Type 1 Diabetes, has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
Phase 4
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

We hypothesize that checking blood sugar and taking long and short acting insulin before lunch at school may improve overall blood sugar control, grades, and decreases school absences in children and teens with poorly controlled T1DM.

Conditions Studied

Interventions

  • DRUG glargine insulin

Study Locations (1)

Texas

  • Texas Children's Diabetes Center - Houston

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2006-06
Est. Completion 2007-06
Phase Phase 4

Sponsor

Baylor College of Medicine

616 total trials

What the Registry Record Tells You About NCT00340613

The ClinicalTrials.gov registry entry for NCT00340613 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which glargine insulin is the first listed.

NCT00340613 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00340613 about?

NCT00340613 is a clinical study titled "Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes". We hypothesize that checking blood sugar and taking long and short acting insulin before lunch at school may improve overall blood sugar control, grades, and decreases school absences in children and teens with poorly controlled T1DM.

What is the current status of trial NCT00340613?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2006-06. Estimated completion is 2007-06.

What conditions does trial NCT00340613 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT00340613?

The interventions under investigation include: glargine insulin (DRUG).

Who is sponsoring clinical trial NCT00340613?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00340613 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.